Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Denali Therapeutics from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $35.92 average price target.
• DNLI opened at $24.83 and has risen 0.4%; its 52-week range is $12.58 to $27.30, with a market capitalization of approximately $3.94 billion.
• Denali reported a quarterly loss of $0.68 per share, missing estimates by $0.17, although revenue of $3.60 million exceeded forecasts. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Other research analysts have also issued research reports about the stock. UBS Group lifted their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a research note on Friday. Robert W. Baird set a $34.00 price objective on shares of Denali Therapeutics in a research report on Friday. Wedbush restated an "outperform" rating and set a $26.00 price objective on shares of Denali Therapeutics in a report on Monday, July 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Finally, Sanford C. Bernstein reaffirmed a "hold" rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Denali Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $35.92.

Denali Therapeutics Trading Up 0.4%

NASDAQ:DNLI opened at $24.83 on Friday. Denali Therapeutics has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The stock has a market capitalization of $3.94 billion, a PE ratio of -8.74 and a beta of 1.01. The business's 50-day simple moving average is $23.54 and its 200-day simple moving average is $21.28.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same period in the previous year, the company earned ($0.72) EPS. Sell-side analysts expect that Denali Therapeutics will post -2.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently bought and sold shares of DNLI. BlackRock Inc. acquired a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $360,759,000. Norges Bank acquired a new position in Denali Therapeutics during the fourth quarter worth $84,525,000. ADAR1 Capital Management LLC boosted its holdings in Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock worth $35,932,000 after purchasing an additional 1,819,339 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Denali Therapeutics by 77.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company's stock valued at $63,329,000 after purchasing an additional 1,672,098 shares in the last quarter. Finally, Temasek Holdings Private Ltd grew its position in Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company's stock valued at $115,784,000 after purchasing an additional 1,657,142 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source